Australia - engleză - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 400 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - rivastigmine tartrate (unii: 9iy2357jpe) (rivastigmine - unii:pki06m3iw0) - rivastigmine 1.5 mg - exelon is indicated for the treatment of mild-to-moderate dementia of the alzheimer's type (ad). exelon is indicated for the treatment of mild-to-moderate dementia associated with parkinson’s disease (pd). exelon is contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see description (11)] - a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see warnings and precautions (5.2)] isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . risk summary there are no adequate data on the developmental risks associated with the use of exelon in pregnant women. in animals, no adverse effects on embryo-fetal development were observed at oral doses 2-4 times the maximum recommended human dose (mrhd) (see data) . the background risk of major birth d

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

mckesson corporation dba sky packaging - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride 75 mg - bupropion hydrochloride tablets are indicated for the treatment of major depressive disorder (mdd), as defined by the diagnostic and statistical manual (dsm) . the efficacy of bupropion hydrochloride tablets in the treatment of a major depressive episode was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult subjects with mdd [see clinical studies ( 14 )] . risk summary data from epidemiological studies of pregnant women exposed to bupropion in the first trimester indicate no increased risk of congenital malformations overall. all pregnancies, regardless of drug exposure, have a background rate of 2% to 4% for major malformations, and 15% to 20% for pregnancy loss. no clear evidence of teratogenic activity was found in reproductive developmental studies conducted in rats and rabbits; however, in rabbits, slightly increased incidences of fetal malformations and skeletal variations were observed at doses approximately equal to the maximum recommended human

Regatul Unit - engleză - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - etoricoxib - oral tablet - 30mg

Australia - engleză - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paroxetine hydrochloride, quantity: 22.22 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; microcrystalline cellulose; mannitol; basic butylated methacrylate copolymer; titanium dioxide; purified talc; polyvinyl alcohol; sodium lauryl sulfate; glyceryl monostearate - treatment of major depression and for the prevention of relapse of depressive symptoms; treatment of obsessive compulsive disorder and for the prevention of relapse of ocd; treatment of panic disorder and for the prevention of relapse of panic disorder; treatment of social anxiety disorder/ social phobia; treatment of generalised anxiety disorder; and treatment of post-traumatic stress disorder

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - paroxetine hydrochloride, quantity: 22.2 mg - tablet, film coated - excipient ingredients: mannitol; titanium dioxide; magnesium stearate; copovidone; colloidal anhydrous silica; microcrystalline cellulose; hypromellose; sodium starch glycollate; purified talc - paroxetine gh is indicated for the treatment of : - major depression and for the prevention of relapse of depressive symptoms - obsessive compulsive disorder (ocd) and prevention of relapse of ocd - panic disorder and for the prevention of relapse of panic disorder - social anxiety disorder/social phobia - general anxiety disorder - post-traumatic stress disorder.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

solco healthcare us, llc - paroxetine hydrochloride hemihydrate (unii: x2els050d8) (paroxetine - unii:41vrh5220h) - paroxetine 10 mg - major depressive disorder: paroxetine tablets are indicated for the treatment of major depressive disorder. the efficacy of paroxetine tablets in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology: clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine tablets in hospitalized depressed patients have not been adequately studied.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paroxetine hydrochloride, quantity: 22.2 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate; lactose; hyprolose; hypromellose; macrogol 8000; titanium dioxide - treatment of major depression and prevention of relapse of depressive symptoms. treatment of obsessive compulsive disorder (ocd) and prevention of relapse of ocd. treatment of panic disorder and prevention of relapse of panic disorder. treatment of social anxiety disorder / social phobia. treatment of generalised anxiety disorder. treatment of post-traumatic stress disorder.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paroxetine hydrochloride, quantity: 22.22 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; microcrystalline cellulose; mannitol; basic butylated methacrylate copolymer; titanium dioxide; purified talc; polyvinyl alcohol; sodium lauryl sulfate; glyceryl monostearate - treatment of major depression and for the prevention of relapse of depressive symptoms; treatment of obsessive compulsive disorder and for the prevention of relapse of ocd; treatment of panic disorder and for the prevention of relapse of panic disorder; treatment of social anxiety disorder/ social phobia; treatment of generalised anxiety disorder; and treatment of post-traumatic stress disorder